COOPER COMPANIES, INC. director Teresa S. Madden reported routine equity compensation activity involving restricted stock units and common shares. On April 1, 2026, she exercised 3,322 restricted stock units into 3,322 shares of common stock at $0.00 per share, increasing her direct common stock holdings to 15,679 shares.
On the same date, she received a new grant of 3,779 restricted stock units, each representing one share of common stock, scheduled to vest on April 1, 2027. A related footnote explains that this award has no expiration date and that the units will either vest or be forfeited, underscoring their service-based nature rather than being a market transaction.
Cooper Companies director Cynthia L. Lucchese reported compensation-related equity activity. On April 1, 2026, she exercised 3,322 Restricted Stock Units, acquiring the same number of common shares at a stated price of $0.00 per share. She also received a new grant of 3,779 Restricted Stock Units, which are scheduled to vest on April 1, 2027. After these transactions, she holds 12,767 shares of Cooper Companies common stock directly. A footnote explains the RSU award has no expiration date and that units will either vest or be forfeited.
Cooper Companies director Lawrence Erik Kurzius reported equity compensation activity involving restricted stock units and common stock. He exercised 3,322 Restricted Stock Units into 3,322 shares of Common Stock at a stated price of $0.00 per share, converting a derivative award into stock ownership.
He also received a new grant of 3,779 Restricted Stock Units, which have no expiration date and will either vest or be forfeited according to the award terms. Following these transactions, he directly owns 11,099 shares of Common Stock and holds 3,779 Restricted Stock Units, reflecting routine compensation-related acquisitions rather than open-market buying or selling.
Cooper Companies, Inc. ownership filing amended: The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0%. The amendment explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with disaggregated reporting by subsidiaries. filing signed March 26, 2026.
The Cooper Companies reported higher quarterly sales and profit for the three months ended January 31, 2026. Net sales rose to $1,024.1 million from $964.7 million, driven mainly by growth in CooperVision contact lenses and steady gains in CooperSurgical office, surgical, and fertility products.
Net income increased to $130.8 million from $104.3 million, with diluted earnings per share up to $0.66 from $0.52. CooperVision delivered operating income of $210.2 million and CooperSurgical $26.8 million, as overall operating margin improved to 21%. Operating cash flow strengthened to $260.9 million, supporting $102.2 million of capital spending and $92.5 million of share repurchases.
The company ended the quarter with total assets of $12,424.2 million and total debt of $2,499.7 million. Subsequent amendments extended the maturity of $950.0 million of term loans to 2031. Cooper also disclosed a U.K. payroll tax dispute with a reasonably possible loss range of £0–£71.7 million, plus interest, for which no liability has been recorded.
CooperCompanies reported a solid fiscal first quarter 2026, with revenue of $1.024 billion, up 6% from a year earlier and 3% organically. Growth was led by CooperVision, where revenue rose 8% to $695.1 million, while CooperSurgical revenue increased 3% to $329.0 million.
GAAP diluted EPS grew to $0.66, up 27%, and non-GAAP diluted EPS rose to $1.10, up 20%, as operating margin improved to 21% on a GAAP basis and 27% on a non-GAAP basis. Free cash flow was $158.7 million, supporting $92.5 million of share repurchases. The company raised its fiscal 2026 outlook, guiding total revenue to $4.306–$4.346 billion, non-GAAP EPS to $4.58–$4.66, and free cash flow to $600–$625 million.
CooperCompanies presents its 2026 annual meeting proxy, highlighting 2025 results, governance and executive pay. Stockholders are asked to elect nine directors, ratify KPMG as auditor, and approve a non-binding say-on-pay vote, with the Board recommending “FOR” on all three proposals.
In fiscal 2025, revenue reached $4.09 billion, up 5% from 2024, with GAAP diluted EPS of $1.87, non-GAAP diluted EPS of $4.13, and free cash flow of about $434 million. The company repurchased $290.1 million of stock, roughly 4.1 million shares, and the Board expanded the share repurchase authorization to $2 billion, leaving nearly $1 billion available.
Cooper completed major restructuring and integration work, recording approximately $89 million in related charges and expecting about $50 million in annual pre-tax savings from fiscal 2026. The proxy emphasizes an independent Board, robust committee structure, strong ESG and cybersecurity oversight, and a pay-for-performance program where most executive compensation is performance-based.
CooperCompanies executive Brian G. Andrews, EVP, CFO & Treasurer, reported an amended stock option award. The filing corrects the number of shares issuable under a previously reported option grant to 41,563 shares of common stock at an exercise price of $99.08 per share.
The options were granted on 12/10/2024, are held directly, and expire on 12/10/2034. They vest at 25% per year over four years starting on the grant date, reflecting time-based equity compensation rather than an open-market stock purchase or sale.
Cooper Companies’ President & CEO, who is also a director, received a grant of stock options covering 184,069 shares of common stock on 12/10/2024. The options have an exercise price of $99.08 and expire on 12/10/2034.
The Form 4/A states it is filed solely to correct the number of shares issuable upon exercise of this previously reported option grant. The options vest at 25% per year over four years beginning on the grant date, and the full 184,069 options are reported as directly beneficially owned.
The Cooper Companies, Inc. amended its debt agreements to adjust terms on its term loan and revolving credit facilities. The company extended the maturity of $950 million of term loans to February 3, 2031, while keeping the maturity date for the remaining $550 million of term loans unchanged.
The amendment also removes the prior credit spread adjustment and raises the cap on incremental term loans to the greater of $1.365 billion and 100% of consolidated EBITDA. Pricing on the term loans can now be based either on the company’s non-credit enhanced, senior unsecured long-term debt ratings or on its consolidated net indebtedness to consolidated EBITDA ratio.
A related amendment to the revolving credit agreement aligns its provisions with the revised term loan agreement, including the removal of credit spread adjustments.